Immatics shares early bispecific data as it seeks to make its name beyond cell therapy

Immatics is planning to advance two T cell receptor-based bispecific antibodies based on results reported Wednesday across Phase 1 trials. The company’s bispecific work previously faced questions when Bristol Myers Squibb ...